Introduction {#Sec1}
============

Cancer is a complex set of diseases that represent almost one-third of the leading causes of death and disability worldwide \[[@CR1]\]. Although the tumors widely differ from their genetic and molecular basis, phenotypic manifestations and variability on the prognosis, they share common hallmarks such as self-sustained proliferative abilities, sustained angiogenesis, drastic metabolic alterations, or the capability to invade surrounding tissues and metastasize \[[@CR2]\]. In addition, a relevant number of human tumors display dysregulation on autophagy, the essential cellular housekeeping mechanism that enables eukaryotic organisms to maintain cellular homeostasis and normal function by degrading and turning over damaged organelles and misfolded proteins \[[@CR3], [@CR4]\]. In tumors with enhanced autophagy, its inhibition affects tumor cell survival under metabolic and chemotherapy stresses. On the other hand, excessive autophagy induction by cytotoxic drugs or autophagy inducers may also lead to autophagic cell death. Hence, the modulation of autophagy represents a therapeutic approach for different types of cancers \[[@CR5]\]. Traditional chemotherapeutic drugs present a variety of side effects such as low specificity, irregular distribution in tissues and organs, rapid drug clearance and biodegradation \[[@CR6]\]. Therefore, new cancer treatments are desired, such as those derived from nanomedicine. This field of research can be defined as nanotechnology applied to human health and provides novel approaches for treating many human diseases, including cancer \[[@CR7]\]. The majority of nanomaterials exhibit unique properties that make them useful for a variety of biotechnological applications. These properties have been exploited to create effective therapeutic and/or diagnostic tools \[[@CR8], [@CR9]\]. Nanomaterials can be used as cytotoxics, and/or enhancers of standard chemotherapies, as well as, drug delivery systems, reducing the side effects of conventional drugs \[[@CR10], [@CR11]\]. A number of nanomedicines have been assessed in clinical trials in combination with various therapeutic agents, mainly anticancer drugs, and many more are expected to be approved by the Food and Drug Administration (FDA) in the near future \[[@CR12], [@CR13]\]. Interestingly, several studies have reported the ability of various types of nanomaterials to exert a cytotoxic effect by modulating the autophagy process \[[@CR14], [@CR15]\]. Despite the risk of their inherent toxicity in immunity cells, and cardiovascular and neurological systems, nanomaterials may serve as therapeutic agents against autophagy-related diseases \[[@CR14], [@CR15]\]. In this review, we summarize the recent studies on the capability of nanostructures to promote cell death by autophagy overstimulation in cancerous cells. Furthermore, to better introduce the reader to this topic we have included some sections dealing with autophagy, where its mechanisms and implications are detailed, as well, as some uses of nanomaterials in nanomedicine.

Macroautophagy {#Sec2}
==============

Macroautophagy (commonly referred to as autophagy) is an intracellular degradative process by which damaged macromolecules and organelles are targeted by autophagic vesicles to lysosomes and then eliminated. Autophagy is crucial to maintain primary biological activities during cellular stresses, such as nutrient starvation \[[@CR16]\]. Once autophagy is activated, the cellular components are embedded into double-membrane vesicles (autophagosomes), which fuse with lysosomes to form an autophagolysosome structure to degrade its contents by lysosomal hydrolases providing a nutrient source for maintaining vital cellular activities \[[@CR17]\]. Autophagy requires the activation of some autophagy-related genes (ATGs), which play a pivotal role in the formation of double-membrane autophagosome vesicles and the stimulation of the autophagy machinery \[[@CR18], [@CR19]\]. Vesicular protein sorting 34 (Vps34), belonging to the class III PI-3 kinases, has been described to interact with Beclin-1 and other autophagy-related proteins playing a critical role in autophagy initiation \[[@CR19]\]. Importantly, the ubiquitin-like conjugation systems are necessary for the activity of specific ATG proteins \[[@CR20]\]. In particular, the mammalian homolog of ATG8, also called LC3B, is expressed as a full-length cytosolic protein that, upon induction of autophagy, is proteolytically cleaved by ATG4, a cysteine protease, to generate LC3B-I. The carboxy-terminal glycine exposed by ATG4-dependent cleavage is then activated in an ATP-dependent manner by the E1-like ATG7 and transferred to ATG3, to generate the active isoform LC3B-II. The recruitment and integration of LC3B-II into the growing phagophore are dependent on ATG5--ATG12 interaction, favoring the binding of LC3B-II on both internal and external surfaces of autophagosomes, where it plays a role in both fusion of membranes and in selecting cargo for lysosomal degradation \[[@CR21]\] (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Mechanism of macroautophagy. Cellular stresses induce AMPK signaling that inhibits the anti-autophagic mTOR complex (mTORC1 and mTORC2). Consequently, Beclin-1, ULK1, and Vps34 mediate phagophore formation and autophagy initiation. Recruitment of LC-3 II into the growing phagophore is dependent on ATG5--ATG12 interaction which favors the binding of LC3B-II on both internal and external surfaces of autophagosomes, where it plays a role in both fusion of membranes with lysosomes and in selecting cargo for lysosomal degradation. Depending on the nature of the stimulus and by cellular context, autophagy acts as a pro-survival mechanism by maintaining vital cellular activities, or drives cell death-type-II, thus acting as tumor suppressor event

AMPK and mTOR: the regulators of autophagy {#Sec3}
------------------------------------------

The nutrient energy sensor AMP-activated protein kinase (AMPK) is the master regulator of autophagy. It inhibits mTORC1 through phosphorylation of TSC2 and Raptor in response to cellular energy cues \[[@CR22], [@CR23]\] and the AMPK-dependent ULK1 phosphorylation is a required step to trigger the autophagy machinery \[[@CR24]\]. Under energetic stress, autophagy initiators unc-51-like kinase 1 (ULK1) complex promotes autophagy by targeting several downstream crucial autophagy effectors involved in the initiation of the process, such as the actin-associated motor protein myosin II and ATG9 \[[@CR24]\]. Mammalian target of rapamycin (mTOR), a serine/threonine protein kinase with large molecular size, belongs to the phosphatidylinositol kinase-related kinase (PIKK) family and it is implicated in the regulation of multiple cellular processes including cell growth, cell cycle, cell survival, as well as autophagy. The observation that treatment with mTOR inhibitors, such as rapamycin, is sufficient to induce autophagy even in the presence of nutrients represents valid evidence for the conclusion that mTOR complex is a powerful repressor of autophagy \[[@CR25]\]. mTOR is composed of two multiprotein enzymatic functional complexes, mTORC1 and mTORC2 \[[@CR26]\]. Contrarily to mTORC2, mTORC1 is sensitive to the inhibition by rapamycin, and it is directly regulated by the cellular nutrient status, including growth factors and amino acid availability, playing essential roles in the regulation of protein translation and autophagy \[[@CR26]\]. Although mTORC2 was discovered recently, it has already been demonstrated that mTORC2 plays a role in chaperone-mediated autophagy \[[@CR27]\] and could activate autophagy via FoxO3 \[[@CR28]\]. Interestingly, mTORC2 phosphorylates and activates Akt, which has a role in the regulation of cell proliferation, survival, metabolism, and transcription \[[@CR26]\]. Genetic and biochemical studies demonstrated that the inhibition of ULK1 by mTOR is a crucial mechanism involved in autophagy repression \[[@CR29]\]. Importantly, recent studies showed that mTOR can phosphorylate ULK1 on Ser757 to favor autophagy blockage \[[@CR24]\]. Several studies indicate that wild-type p53 protein triggers autophagy in cancer cells through various mechanisms including the stimulation of AMPK, the inhibition of the mTOR (by upregulation of PTEN and TSC1), and the induction of DRAM1 \[[@CR30]\]. The functional interplay between AMPK and wtp53 is a well-described mechanism involved in tumor suppression. Indeed, the stimulation of AMPK by energy stress promotes the phosphorylation and activation of wtp53 \[[@CR31], [@CR32]\]. Moreover, AMPK can increase both the activity and the stability of wtp53 through direct phosphorylation of p53 and inactivation of MDMX-mediated ubiquitination process, thus prolonging the half-life of wtp53 itself \[[@CR33]\]. Wtp53 may, in turn, increase AMPK activity through transcriptional activation of the gene encoding the β subunit of the enzymatic complex \[[@CR34]\] and Sestrins \[[@CR35]\], providing positive feedback that sustains an autophagic AMPK signaling.

Mitophagy: a specialized form of autophagy {#Sec4}
------------------------------------------

Mitochondria are cellular organelles playing a crucial role in energy metabolism, regulation of cell signaling and apoptosis in eukaryotic cells \[[@CR36]\]. To maintain cellular homeostasis, the cell has evolved complex systems for the quality control and clearance of mitochondria. Mitophagy is a selective form of autophagy, by which dysfunctional or damaged mitochondria are selectively targeted by autophagosomes and delivered to lysosomes to be recycled by the cell. Hence, mitophagy represents an essential quality control mechanism to ensure mitochondrial network's integrity and functionality. Similarly to macroautophagy, mitophagy is tightly regulated by a variety of proteins controlling each phase of the process, to ensure the selective sequestration of those mitochondria that need to be eliminated, in the forming autophagosome. Efficient mitophagy occurs during some vital biological processes through Parkin-dependent and Parkin-independent pathways, and allows the damaged organelles to be targeted into the nascent autophagosome, without affecting the entire mitochondrial network \[[@CR37], [@CR38]\]. However, an extensive or uncontrolled mitophagy can lead to bioenergetic failure, whereas excessive mitochondrial biogenesis can generate high levels of reactive oxygen species (ROS) and promote apoptosis or cell survival depending on the type of stimulus and the cellular context \[[@CR38]\]. Therefore, the maintenance of a balanced healthy mitochondrial population through both processes is essential for cellular function and survival \[[@CR39]\]. Defects in mitophagy machinery are linked to most of the neurodegenerative diseases \[[@CR40]\], to tumorigenesis, neoplastic progression and chemoresistance \[[@CR41], [@CR42]\]. Therefore, we hypothesize that pharmacological modulation of mitophagy could represent a potent strategy against many human diseases.

Autophagy in cancer {#Sec5}
-------------------

Autophagy has been described to play a role in physiological processes, mammalian development and a variety of human diseases, including cancer, neurodegenerative diseases and muscular disorders \[[@CR43]\]. Autophagy regulation is strictly interconnected with the aberrant setting of cancer cell metabolism as revealed by the fact that mTOR and AMPK pathways are both the master regulators of autophagy and the most critical sensors of the cellular energy status \[[@CR44]\]. In particular, the mTOR complex stimulates anabolic biosynthesis for cancer cell growth and inhibits autophagy, while AMPK signaling triggers the degradation of macromolecules, including lysosomal autophagic catabolism \[[@CR45]\]. The role of autophagy in regulating cancer cell death or survival remains highly controversial and it is likely reliant on the tumor type, the stage of neoplasia and the cellular context, as well as by metabolic context in which the cells lie \[[@CR46]\].

Some studies support the idea that, in established tumors, constitutive autophagy may have a protective role in cancer cells by removing damaged organelles or recycling misfolded macromolecules \[[@CR47]\]. In support of this hypothesis, several studies report that autophagy tries to fulfill the high metabolic demands of the proliferating tumor cells exposed to stressful conditions, such as nutrient deprivation, oxidative stress, hypoxia, or in response to therapy \[[@CR46], [@CR48]\]. Hypoxic microenvironments trigger HIF-1α-dependent and -independent autophagy, which also contributes to tumor survival \[[@CR49]\]. Interestingly, cancers harboring activating KRAS mutations have a high basal rate of autophagy, even in growth conditions \[[@CR50]\]. It has been reported that pharmacological and genetic inhibition of autophagy results in tumor regression in pancreatic cancer xenografts and genetic mouse models \[[@CR50], [@CR51]\]. Thus, by enhancing stress tolerance and providing an alternative nutrient source by which cancer cells can meet their massive nutrient and energy demands, autophagy appears to serve as a pro-survival mechanism for tumor cells.

However, it is also well established that cancer cells having uncontrolled autophagy can also undergo cell death, also called cell death-type II, likely due to excessive degradation of cellular constituents and organelles required for homeostasis of the cells. Hence, autophagy has been widely established as a tumor-suppressive mechanism, and cancer cells can escape from extensive autophagic cell death resulting in the enhancement of ROS production, genomic instability, and tumor progression \[[@CR54]\]. Defects in autophagy cause the accumulation of abnormal mitochondria that are a potential source of ROS that lead genomic instability, and cancer initiation and progression \[[@CR52]\]. Moreover, autophagy dysfunctions cause also activation of the DNA damage response, DNA copy number variations, and genetic instability, which lead to the acquisition of genome mutations that drive tumorigenesis \[[@CR53]\]. This situation of chronic tissue damage also provokes an inflammatory response that can, in turn, sustain tumor growth through cytokine and chemokine productions \[[@CR54]\]. Thus, tumor promotion conferred by autophagy defects may result from both mutagenesis and the creation of an inflammatory environment. In this sense, it has been reported that mice having monoallelic deletion of the autophagy-related gene beclin1 develop spontaneous tumors. Allelic loss of beclin1 was also observed in 40--75% of breast, ovarian, and prostate cancers \[[@CR3], [@CR55]\]. In addition, accumulation of autophagy adaptor protein, p62/SQSTM1, as a result of the inhibition of autophagy, was reported to be responsible for the tumorigenesis by multiple mechanisms \[[@CR56]\].

This evidence strongly suggests that autophagy is an important mechanism that suppresses tumor initiation and, when impaired, may lead to tumorigenesis. Recently, several studies have demonstrated that mutant p53 proteins exert oncogenic ability that leads to high genomic instability, reduced response to chemotherapy and generally poor clinical outcome of cancer patients \[[@CR57]\]. Interestingly, contrarily to the wild-type counterpart, mutant p53 proteins can inhibit autophagy machinery through the stimulation of mTOR signaling pathway \[[@CR58], [@CR59]\] and the inhibition of AMPK \[[@CR60], [@CR61]\]. This oncogenic ability represents an essential turning point to sustain cancer cell proliferation and growth. On the other side, autophagy can trigger mutp53 protein degradation in a functional interplay that can regulate tumor progression and the response to antitumor therapies \[[@CR62]\].

Autophagy in other diseases {#Sec6}
---------------------------

Neurodegenerative diseases, such as Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS), are characterized by the progressive loss of neurons and/or neuronal functions. These syndromes are developed by the presence of aggregate-prone neurotoxic proteins, in the form of aggresomes and/or inclusion bodies, as well as by the presence of dysfunctional mitochondria \[[@CR63]\]. In this regard, autophagy protects against neurodegenerative diseases acting as a quality-control system and by removing protein aggregates and damaged organelles. Therefore, it represents an essential process for the maintenance of neuronal homeostasis \[[@CR64]\]. Recent findings have highlighted that autophagy has a crucial role also in the control of muscle mass \[[@CR65]\]. Overstimulated autophagy is harmful to myofiber health and is involved in some inherited muscle diseases \[[@CR65]\]. However, also defective autophagy clearance favors the aggregation of misfolded proteins and damaged organelles, and contributes to the pathogenesis of different forms of muscular dystrophies and congenital myopathies \[[@CR65]--[@CR67]\]. Interestingly, recent observations suggest that re-establishing a proper autophagic flux with pharmacological treatments might represent a promising strategy for counteracting muscle loss in muscular disorders \[[@CR68]\]. Autophagy pathway plays a central role in the cellular quality control, metabolic adaptation and clearance of misfolded proteins and/or damaged organelles in a plethora of human diseases, and the pharmacological modulation of this process may represent a valid therapeutic challenge \[[@CR77]\].

Current cancer treatments based on autophagy modulation {#Sec7}
-------------------------------------------------------

In tumors with enhanced autophagy, as a mechanism of survival and chemoresistance, the inhibition of autophagy can suppress the ability of tumor cells to survive under cellular metabolic stress \[[@CR69], [@CR70]\] making them more prone to initiate cell death mechanisms. In this sense, there are a variety of examples showing that autophagy inhibitors, when used in combination with anticancer drugs, may sensitize chemoresistant cells, thus inhibiting tumor survival \[[@CR47], [@CR71]\]. For example, it has been reported that inhibition of autophagy function by depletion of Atg5, Atg7 or beclin1 may revert the acquired resistance against tamoxifen in HER-positive breast cancer cells \[[@CR72]\]. The combinatorial treatment consisting of autophagy inhibitor 3-methyl-adenine (3-MA) and trastuzumab (Tmab) in HER2-positive breast cancer cells can increase the potency of chemotherapy \[[@CR73]\]. Increased autophagy is also associated with cisplatin resistance in ovarian cancer cells, and Atg5 deletion in these cells induces apoptotic cell death \[[@CR74]\].

Among the multiple compounds that inhibit the different phases of autophagy, nowadays the only clinically approved autophagy inhibitor by the FDA is the anti-malarial chloroquine (CQ) and its derivatives, such as hydroxychloroquine (HCQ) \[[@CR75]\]. HCQ belongs to the class of lysosomotropic agents that can inhibit lysosomal acidification and prevent the degradation of autophagosomes, thereby suppressing autophagy \[[@CR76]\]. HCQ has been shown to have antineoplastic effects in numerous preclinical experiments when combined with other agents \[[@CR77]\]. In renal cell carcinoma lines, HCQ enhanced the cytotoxicity of mTOR inhibitor, such as temsirolimus, promoting apoptosis and causing the downregulation of phospho-S6 through a mechanism not found in other autophagy inhibitors, such as bafilomycin A1 \[[@CR78]\]. In breast cancer cells, the combination of HCQ and tamoxifen (TAM) was more effective at inhibiting autophagy than monotherapy in estrogen receptor-positive (ER+) breast cancer cell lines \[[@CR79]\]. Frequently, cancer cells treated with chemotherapy drugs exhibit autophagy induction that serves as survival mechanism. However, excessive autophagy induction upon cytotoxic drug treatment or using autophagy inducers may also lead to autophagic cell death. It has been reported that glioblastoma cells resistant to apoptosis die when treated with alkylating agents such as temozolomide and tyrosine kinase inhibitors such as dasatinib, where both induce autophagy \[[@CR80]\]. Similarly, histone deacetylase (HDAC) inhibitors have also shown autophagy-inducing potential as one of its anticancer effects \[[@CR81]\]. Proteasome inhibitors (PI) have also been shown to stimulate autophagy. Bortezomib, a PI used in the treatment of multiple myeloma and mantle cell lymphoma, has been shown to increase the early formation of autophagosomes and LC3-II, demonstrating the inducing effects on autophagy \[[@CR82]\]. A well-known class of autophagy inductors includes analogs of the mTOR inhibitor rapamycin, such as temsirolimus and everolimus. These compounds, used alone or in conjunction with chemotherapy drugs, show an antiproliferative effect in mantle cell lymphoma and acute lymphoblastic leukemia by overstimulating autophagy, which might cause tumor cell death \[[@CR83], [@CR84]\]. Everolimus has been approved for use by the FDA as an angiogenesis inhibitor in renal cell carcinoma, advanced breast cancer, and pancreatic neuroendocrine tumors \[[@CR85], [@CR86]\]. However, it is not clear whether the induction of autophagy by everolimus contributes to its anti-angiogenesis ability. However, in clinical trials, current targeted anticancer treatments based exclusively on mTOR inhibition have demonstrated high resistance rates \[[@CR87], [@CR88]\] (Table [1](#Tab1){ref-type="table"}). Numerous ongoing phase I/II clinical trials are investigating the combination of HCQ with mTOR inhibitors in renal cell cancer, multiple myeloma and advanced solid tumors as reviewed by Duffy et al. \[[@CR71]\]. The large number of ongoing trials demonstrates the enormous relevance that autophagy modulation can have, in combinatory treatments, to overcome the resistance to existing cancer therapies (Fig. [2](#Fig2){ref-type="fig"}).Table 1Some examples of current cancer treatments based on autophagy modulationEntryDrugsTargetType of cancerStatus of the studyEffect on autophagyBiological effectReferences1ChloroquineLysosomesBreast cancerApproved by FDAInhibitoryInhibition of a protective autophagy\[[@CR75]\]2HydroxychloroquineLysosomesEsophageal, hepatocellular carcinoma, lung, pancreatic cancerApproved by FDAInhibitoryInhibition of a protective autophagy\[[@CR75]\]3Hydroxychloroquine + erlotinibLysosomes, EGFRAdvanced non-small cell lung cancerPhase I clinical trialInhibitorySafe and well tolerated\[[@CR77]\]4Hydroxychloroquine + temsirolimusLysosomes, mTOR pathwayMetastatic renal cancerCancer cell linesInhibitoryApoptosis, mitochondrial damage, mTOR downregulation\[[@CR78]\]5Hydroxychloroquine + tamoxifenLysosomes, estrogen receptor-α (ERα)Breast cancerCancer cell lines, in vivo models, phase I clinical trialInhibitoryReduced drug resistance and potentiation of antiestrogenic therapy in vitro and in vivo\[[@CR79]\]6Temozolomide, dasatinibAlkylating agents, tyrosine kinase inhibitorsGlioblastomaCancer cell lines, phase I clinical trialInductionIncreased therapeutic efficacy of temozolomide, apoptosis of resistance cells\[[@CR80]\]7Histone deacetylase inhibitorsHistone deacetylaseHepatocellular carcinomaCancer cell linesInductionAutophagy cell death\[[@CR81]\]8BortezomibProteasomeProstate cancerCancer cell linesInductionAutophagy protective\[[@CR82]\]9Temsirolimus + vorinostatmTOR pathway, histone deacetylaseLymphomaCancer cell linesInductionSynergistic antiproliferative activity, apoptosis, autophagy cell death\[[@CR83]\]10Everolimus + vincristinmTOR pathway, tubulinAcute lymphoblastic leukemiaIn vivo modelsInductionSynergistic tumor growth reduction, cell death, and survival of engrafted mouses\[[@CR84]\]11Rapamycin, everolimusmTOR pathwayCancer metastasisIn vivo modelsInductionMetastatic tumor growth, angiogenesis, reduced cancer recurrence\[[@CR85]\]12EverolimusmTOR pathwayMetastatic renal cell carcinomaPhase III clinical trialInductionProlongation of tumor-free survival\[[@CR86]\]13Hydroxychloroquine + temsirolimusmTOR pathwayMelanomaThree-dimensional spheroid cultures, in vivo modelsInductionTumor growth suppression, cell death, apoptosis\[[@CR87]\]14EverolimusmTOR pathwayLymphomaCancer cell linesInductionProtective autophagy, drug resistance\[[@CR88]\]Fig. 2The dual role of autophagy in cancer. A variety of cellular stresses, including (1) nutrient deprivation, (2) oxidative stress, (3) hypoxia and (4) chemotherapy, can result in the induction of a protective autophagy leading tumor progression and chemoresistance. However, the same stresses can also induce and autophagy with tumor suppressor role. Indeed, cancer cells having an uncontrolled extensive autophagy can also undergo cell death-type II, likely due to excessive degradation of cellular constituents and organelles. Importantly, the inhibition of protective autophagy leads to apoptotic and necrotic cell death. In contrast, the inhibition of autophagy cell death (for instance by oncogenic mutant p53 isoforms) may lead to tumorigenesis through mTOR signaling and ROS

Nanomaterials as therapeutic tools {#Sec8}
==================================

Recent progress in nanotechnology offers plenty of tools to fight cancer with innovative, personalized and efficient therapeutic agents by overcoming barriers or drawbacks usually encountered with traditional drugs \[[@CR89]\]. The recent advances in the field of chemistry and material science have produced nanomaterials which are expected to improve the treatment of many diseases otherwise resistant to the traditional therapeutic approaches. Nanomaterials can act as cytotoxics and/or enhance the efficacy of standard chemotherapies. Moreover, they represent novel drug delivery systems thereby decreasing the side effects of conventional drugs. These nanomaterials exhibit unique physical, chemical, mechanical and optical properties that make them suitable as novel and powerful therapeutic tools. Depending on their morphology, size and chemical properties, nanomaterials are broadly divided into various categories, including liposomes, carbon-based materials, polymers, metals, metals oxide, and ceramics. Most of these nanomaterials are used as nanocarriers to deliver therapeutic molecules, such as drugs, proteins or nucleic acids \[[@CR90]--[@CR99]\].

One of the major challenges of nanomedicine consists of developing drug delivery systems to transfer drugs, proteins, enzymes or antibody into specific target sites without affecting healthy tissues. The primary physical, chemical, and biological advantages in the use of nanocarriers include the nanoscale sizes, high surface-to-volume ratios, favorable drug release profiles and targeting modifications \[[@CR6]\]. Interestingly, nanocarriers can passively accumulate in the leaky vasculature, typical of tumor tissues in a manner known as the enhanced permeability and retention effect (EPR) \[[@CR100]\]. Nanocarriers may also be conjugated with specific ligands, to utilize active targeting mechanisms \[[@CR101]\]. This allows them to reach specific tissues and release drugs in a stable and controlled manner. Therefore, through active targeting, the use of nanomaterials in drug delivery can modify the pharmacokinetic and pharmacodynamic profiles of drugs, thereby enhancing their therapeutic index \[[@CR100], [@CR102]\]. Microenvironmental stimuli can trigger the release of drugs by evoking a change in the nanocarriers, to ensure specific toxicity to the target tissue, while does not affect the healthy tissue \[[@CR10]\]. Changes in pH, redox, ionic strength, and stress in target tissues are examples of internal stimuli \[[@CR7], [@CR13]\]. External stimuli, including temperature, light, ultrasound, magnetic force, and electric fields, also can trigger the release of drugs \[[@CR7]\] (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Passive and active targeting of nanoparticles in cancer treatment. Passive tumor targeting is achieved by extravasation of nanoparticles through increased permeability of the tumor vasculature (EPR effect). Active tumor targeting (left inset) can be achieved by functionalization of nanoparticles with targeting ligands that promote cell-specific recognition and binding. Once internalized, the nanoparticles can express their cytotoxic potential by releasing the drug and/or another compound

Among the different nanostructures, metallic nanoparticles are particularly relevant due to their inherent reactivity, which can be used for therapeutic purposes, such as hyperthermia. Hyperthermia-based approaches \[[@CR103]\] consist of exposing the body to high temperatures to kill cancer cells or sensitizing them to the effects of radiation and certain anticancer drugs. The use of metallic nanoparticles allows for the application of a variety of techniques such as laser, ionizing radiation and microwaves, to induce heat at the nanoparticles area \[[@CR103]\]. Magnetic hyperthermia allows to remotely induce local heat using the magnetic energy losses of magnetic nanoparticles under an alternate magnetic field (AMF), thus drastically reducing the harmful side effects at the surrounding healthy tissues \[[@CR104]\]. Importantly, a number of studies describe magnetic hyperthermia as a very attractive adjuvant strategy to radiation and chemotherapy in cancer treatment \[[@CR105]\]. Alternatively, by exposing metallic nanoparticles to laser radiation near their plasmon-resonant absorption band, it is possible to produce local heating of nanoparticle-labeled cells without harming surrounding healthy tissues. Such some promising approaches, which induce the photothermal effect in vitro and in vivo, have been developed over the last years. They include plasmonic photothermal therapy (PPTT) \[[@CR106]\], and red and near-infrared (NIR) laser light irradiations \[[@CR107]\]. Interestingly, massive cancer cell death, reduction of tumoral volume and general improvements in survival have been demonstrated when the gold nanoparticles are actively targeted to tumors in mice over passively targeted nanoparticles \[[@CR108]--[@CR111]\].

Targeting autophagy with metal-based nanoparticles as therapy in cancer diseases {#Sec9}
================================================================================

In this section, we summarize the most recent studies describing the ability of metallic nanoparticles to overstimulate autophagy and mitophagy in cancer cells selectively. This occurs through the dysregulation of some cellular signaling pathways without significantly affecting the level of autophagy in noncancerous cells. The effect of several nanomaterials on autophagy/mitophagy modulation represents an exciting therapeutic approach against different human tumors (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Cytosolic delivery of drug-loaded metallic nanoparticles via receptor-mediated endocytosis and its effect on autophagy and mitophagy modulation. The metallic nanoparticles, once internalization via receptor-mediated endocytosis, release the drugs or other compounds loaded, thus exerting a cytotoxic effect against cancer cells. The release occurs as a consequence of some cellular environmental stimuli, such as changes in pH and redox status by evoking changes in the nanocarrier structure. The toxic effect is exerted in various manners by inducing mitochondrial damage, and autophagy and mitophagy processes that culminate with apoptotic and autophagic cell death

Silver-based nanoparticles {#Sec10}
--------------------------

Different studies showed the enormous therapeutic potential of silver nanoparticles (Ag-NPs) against a plethora of cancer cells. It has been reported that these nanomaterials can modulate autophagy acting as cytotoxic agents itself, in combination with other treatments, as well as nanocarriers to deliver therapeutic molecules \[[@CR112]--[@CR120]\]. For example, it has been shown that Ag-NPs, embedded into a specific exopolysaccharide (EPS), exert a cytotoxic effect against a panel of cancer cell lines. This occurs through the promotion of ROS which, in turn, induced cell death through apoptosis and autophagy stimulations. These observations were further confirmed in SKBR3 cells after Ag-NPs--EPS exposure in which the induction of autophagic markers was detected by fluorescence microscopy and western blot indicating a prominent mechanism of autophagic cell death \[[@CR112]\].

In another study, Ag-NPs have been observed to have a higher cytotoxic effect on PANC1 cancer cells compared to the non-tumor cell of the same tissue. In particular, Ag-NPs decreased the viability of PANC-1 cells and stimulated apoptotic and autophagic cell death more significantly than non-tumor cells. Moreover, the authors observed that the protein level of autophagy marker LC3-II increased substantially in PANC-1 cells treated with Ag-NPs, thus indicating that the apoptotic and necroptotic cell death is occurring with autophagy in adenocarcinoma pancreatic cancer cells \[[@CR113]\].

In a related report, Cisplatin and a reduced graphene oxide--silver nanoparticle nanocomposite (rGO--Ag-NPs) were assessed in HeLa cancer cells. Interestingly, the combination of Cis and rGO--Ag-NPs resulted in more pronounced effects on the expression of autophagy genes and in the accumulation of autophagosomes and autophagolysosomes, which were associated with the generation of ROS and cell death. These findings demonstrate that rGO--Ag-NPs can potentiate Cis-induced cytotoxicity, apoptosis, and autophagy in HeLa cells, and hence rGO--Ag-NPs could be potentially applied to cervical cancer treatment as a powerful synergistic agent with Cis or any other chemotherapeutic agents \[[@CR114]\]. Notably, also the combination of Salymicin (Sal) and Ag-NPs showed a substantial synergistic effect on cytotoxicity and in the accumulation of autophagolysosomes in A2780 ovarian cancer cells. The induction of massive autophagy, in turn, led to mitochondrial dysfunction and cell death, thus representing a relevant therapeutic strategy for the treatment of ovarian cancer \[[@CR115]\].

Moreover, it has been found that the combination of Ag-NPs and radiotherapy significantly enhanced cytotoxic effects in U251 glioblastoma cells and orthotopic mouse brain tumor model. In addition, LC3-II protein level, acridine orange (AO) and monodansylcadaverine (MDC) staining revealed that autophagy was strongly upregulated following the treatment of Ag-NPs with ionizing radiation, suggesting that modulation of the autophagy process may improve glioblastoma therapeutic outcome \[[@CR116]\]. Transcription factor EB (TFEB) is a master regulator of lysosomal biogenesis, and it has been reported to regulate autophagy by upregulating a cluster of autophagic genes, including MAPLC3B, SQSTM1, UVRAG, WIPI, VPS11, VPS18, and ATG9B \[[@CR121], [@CR122]\]. Recently, Ag-NPs have been shown to reduce the expression of TFEB in A459 lung cancer cells, thus affecting lysosome function and autophagic flux, and leading cellular damage \[[@CR123]\].

Gold-based nanoparticles {#Sec11}
------------------------

Gold nanoparticles (Au-NPs) have been extensively explored in biomedical research as drug delivery scaffolds, because of their low toxicity and immunogenicity \[[@CR124], [@CR125]\], good biocompatibility and excellent stability \[[@CR126]\]. Remarkably, the surface of Au-NPs can be easily modified with multiple agents including chemotherapeutics, oligonucleotides, and proteins, making them excellent delivery vehicles.

It has been reported that pH-sensitive polymeric nanoparticles with gold(I) induce cell death in MCF7 breast cancer cell death through regulation of oxidative stress and autophagy \[[@CR127]\]. A recent study describes the development of SMI\#9-tethered Au-NPs using a chemical strategy that allows the intracellular release of SMI\#9, a small inhibitor of Rad6, a central player in DNA damage tolerance, post-replication DNA repair mechanism and mitochondrial stability \[[@CR128], [@CR129]\]. The authors of this study observed an increase in autophagy and apoptotic markers in SUM1315 triple-negative breast cancer (TNBC) cells after treatment with SMI\#9-AuNPs, suggesting an essential role for Rad6 in assuring the survival of cancer cells \[[@CR130]\].

In a related study, gold nanoparticles were modified with the snake venom protein toxin NKCT1 (Au-NPs--NKCT1) and tested in human leukemic U937 and K562 cell lines \[[@CR131]\]. The authors reported that Au-GNPs--NKCT1 treatment exerts its cytotoxic potential by inducing a caspase 3-mediated apoptosis and an autophagic cell death response due to the dysregulation of AKT/mTOR signaling pathways. Therefore, the conjugation of Au-NPs with NKCT1 represents a promising strategy to develop therapies from natural resources such as snake venoms \[[@CR131]\].

It has been reported that Au-NPs, in combination with tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), were able to promote a relevant Drp1-mediated mitochondrial damage leading apoptosis, autophagy and mitophagy activation \[[@CR132]\]. In support of this, the authors found that mitophagy markers PINK1 and Parkin were recruited into mitochondrial fractions and autophagy signature was detected in Calu-1 cells after combined treatment \[[@CR132]\]. Hence, autophagy and mitophagy activations in response to TRAIL combined with Au-NPs may represent a strategy to overcome TRAIL resistance that occurs in many tumors.

The epidermal growth factor receptor (EGFR) is overexpressed in 70--80% of TNBC and has been emerging as a promising target for TNBC treatment \[[@CR133]\]. In a recent report, the role of autophagy was assessed in the cytotoxicity induced by anti-EGFR antibody-conjugated gold nanoparticle (anti-EGFR--Au-NPs)-combined near infrared-photothermal therapy (NIR-PTT) in MDA-MB-231 cancer cells \[[@CR134]\]. Interestingly, the cell death induced by anti-EGFR--Au-NPs-combined NIR-PTT was rescued by treatment with 3-MA. Anti-EGFR--Au-NPs-combined NIR-PTT strongly induced autophagy as evidenced by autophagic vesicles and a significant increase in several autophagy-related markers, accompanying the inhibition of AKT/mTOR signaling pathway. In addition, in mouse xenograft tumors, anti-EGFR--Au-NPs-combined NIR-PTT also increased LC3 and beclin-1 levels. These findings demonstrate that autophagy elicited by anti-EGFR--GNs-combined NIR-PTT is an alternative cell death mechanism, resulting in most effective cancer therapy for EGFR-targeted TNBC \[[@CR134]\].

Tmab is a humanized monoclonal antibody routinely used for patients with HER2-positive breast and gastric cancers that improves survival \[[@CR135]\]. In a recent study, Au-NPs modified with Tmab were evaluated in NCI-N87 and MKN7 HER2-positive gastric cancer. Interestingly, the authors report that T-Au-NPs possessed specific HER2-based tumor selectivity and exerted a potent cytotoxic effect through the induction of autophagy mechanism that differs from those of the non-conjugated Tmab \[[@CR136]\].

Quercetin (3,3′,4′,5,7-pentahydroxy-flavone) is a flavonoid found in a wide variety of plants and constituent in human diet \[[@CR137]\]. Quercetin exhibits beneficial effects on human health and possesses selective antiproliferative and antitumor effects via apoptotic mechanisms on different human cancer cell lines \[[@CR138]\]. It has been reported that gold--quercetin nanoparticles, stabilized by PLGA, induce autophagy cell death and apoptosis through dysregulation of signaling pathways in human liver, cervical and neuroglioma cancer cells \[[@CR139]--[@CR141]\].

Interestingly, it has been observed that monolayers of chiral molecules anchored on the surfaces of Au-NPs ([d]{.smallcaps}-PAV--Au-NPs; [l]{.smallcaps}-PAV--Au-NPs) induced chirality-selective autophagy selectively in MDA-MB-231 cancer cells. Furthermore, the intratumoral injection of [d]{.smallcaps}-PAV--Au-NPs suppresses the tumor growth without side effects in vivo \[[@CR142]\]. This specific effect was likely attributed to the chirality-variant ROS generation, cellular uptake, and their continuous autophagy stimulus.

Layered nanoparticles made with an iron core and a gold shell, Fe\@Au, combine the strong magnetic susceptibility of pure iron and the passivating properties of the gold coating. In practice, the gold shell only delays the oxidation, rather than stopping it entirely \[[@CR143]\]. Fe\@Au-NPs have been reported to exert toxicity in oral and colorectal cancer cells through mitochondria-mediated autophagy and, therefore, have been proposed as a potential anticancer agent \[[@CR144], [@CR145]\].

Metal oxide-based nanoparticles {#Sec12}
-------------------------------

Zinc oxide nanoparticles (ZnO-NPs) are routinely used in industrial products, and more recently, they have been employed in biomedical and cancer applications due to the attractive chemical properties of these nanomaterials \[[@CR146]\]. In a recent study, it has been reported that ZnO-NPs can induce significant cytotoxicity, apoptosis, and autophagy in SKOV3 ovarian cancer cells via induction of intracellular ROS and oxidative stress \[[@CR147]\]. ZnO-NPs have also been shown to induce toxicity in CAL27 oral cancer cell lines by activating PINK1/Parkin-mediated mitophagy \[[@CR148]\].

It has been reported that conjugation of ZnO-NPs with meso-tetra (4-carboxyphenyl) porphyrin (MTCP) could increase their cytotoxic effects through autophagy induction in MCF-7 and MDA-MB-468 breast cancer cells \[[@CR149]\]. These reports strongly suggest a possible application of ZnO-NPs as anticancer agents.

Iron oxide nanoparticles (IO-NPs) are widely used in biomedicine for their multi-functional properties of super-paramagnetism and biocompatibility as well as in cancer treatment due to their drug delivery and multi-imaging functions \[[@CR150]\]. However, some issues concerning their therapeutic efficiency and biological safety limited their development and clinical translation.

Interestingly, IO-NPs have been reported to induce autophagy process through multiple mechanisms including lysosome impairment, mitochondrial damage, and ER stress \[[@CR151]\].

IO/Au-NPs conjugated to anti-EGFR suppress lung tumor growth both in vitro and in vivo, by abrogating G2/M cell-cycle arrest and inducing DNA damage, autophagy and apoptosis \[[@CR152]\].

In an excellent study, researchers have developed chitosan chloride (HTCC)/alginate-encapsulated Fe~3~O~4~ NPs (HTCC--MNPs) and applied them to multi-drug resistance (MDR) gastric cancer models. Interestingly, they reported that the novel HTCC--MNPs were more cytotoxic in both SGC7901 human gastric cancer cell line and MDR variant cell line (SGC7901/ADR) than to normal gastric epithelial cell line (GES). In addition, the co-localization of LC3 with lysosomal marker LAMP2 and an increased LC3-II/LC3-I ratio revealed the induction of autophagy by HTCC--MNPs. Therefore, these data indicated that autophagy was responsible for the cytotoxicity induced by HTCC--MNPs, highlighting that its modulation may have a role in treating MDR gastric cancer \[[@CR153]\]. Moreover, IO-NPs have been shown to selectively induce significant autophagy--lysosome accumulation and cell death through dysregulation of Akt/AMPK/mTOR pathway and in a dispersity-dependent manner, in lung and cervix cancer cells but not in normal cells \[[@CR154], [@CR155]\].

Another study has reported that PEGylated IO-NPs caused severe cytotoxicity in SKOV3 human ovarian cancer cells through multiple mechanisms, such as ROS production and apoptosis induction. Notably, the authors observed changes in autophagosome formation when SKOV3 cells were exposed to PEGylated-IO-NPs by TEM imaging and by detecting the level of autophagy marker LC3-II. The authors concluded that autophagy induction could be a protective role against cytotoxicity IO-NPs-induced \[[@CR156]\].

In another study, it has been shown that IO-NPs photothermal effect could lead to autophagy induction in both MCF-7 cancer cells and MCF-7 xenograft model, in a laser dose-dependent manner, and the inhibition of autophagy would enhance the photothermal cell killing by increasing cell apoptosis. Therefore, this work may provide a potential combination therapeutic approach of autophagy modulators and photothermal agents \[[@CR157]\].

Cuprous (Cu-NPs) and copper oxide nanoparticles (CO-NPs), are other nanomaterials with biomedical application, which showed potential pharmacological effects on tumor therapy by inducing apoptosis, inhibiting metastasis and stimulating autophagic cell death in leukemia, melanoma, and lung and breast cancers \[[@CR158]--[@CR161]\].

In a study by Xia et al., Cu-NPs dramatically affect autophagy pathway in human cervical cancer cell lines, thus leading to inhibition of cell growth and apoptosis. In particular, the authors reported that Cu-NPs could decrease the phosphorylation of AKT and mTOR, strongly suggesting that Cu-NPs could induce autophagy through AKT/mTOR pathway. Moreover, they observed the increase of the autophagosome formation in a time- and concentration-dependent manner. Their work provides preliminary evidence of the therapeutic potential of CO-NPs in the treatment of cervical cancer \[[@CR162]\]. Also, CO-NPs have been reported to induce autophagy in MCF7 human breast cancer cell line, in a time- and dose-dependent manner. The authors of the study hypothesize that autophagy induced by CO-NPs may serve as a cellular defense against their intrinsic toxicity, and inhibition of autophagy could be essential to induce apoptosis in breast cancer cells \[[@CR163]\].

Silica-based nanoparticles {#Sec13}
--------------------------

Many studies have demonstrated that amorphous silica nanoparticles (Si-NPs) possess unique properties such as biocompatibility, tunable pore size, high surface area, and ease of modification. For this reason, Si-NPs have been widely used in gene transfection, drug delivery, biosensing and bioimaging \[[@CR164]--[@CR166]\]. It has been observed that these nanostructures promote osteoblast differentiation through autophagy stimulation \[[@CR167]\]. Si-NPs have also been shown to stimulate ROS generation, oxidative stress and ER stress that lead to autophagy activation via unfolded protein response (UPR) pathways in hepatocytes \[[@CR168]\].

Several other studies reported that through autophagy modulation, Si-NPs exert cytotoxic effect in cancer cells thus highlighting their potential therapeutic effect. It has been reported that Si-NPs can lead to apoptosis, mitophagy, autophagy, and consequently ROS accumulation in glioblastoma LBC3 cells representing a potential therapeutic agent for glioblastoma multiforme therapy \[[@CR169]\].

Intriguingly, it has been shown that accumulation of Si-NPs in human cervix carcinoma cells may lead to lysosomal dysfunctions and autophagy defects, resulting in a reduced metabolic activity of cancer cells \[[@CR170]\]. Recently, genistein--PEGylated silica hybrid nanomaterials (Gen--PEG--SiHNM) have been developed, which possess antiproliferative effects by activating apoptosis and autophagy cell death in HT29 human colon cancer cells \[[@CR171]\]. This study suggests that Gen--PEG--SiHNM may be potentially used as an alternative treatment for colorectal cancer in the near future.

Si-NPs have also been observed to induce ROS and autophagy dysfunction in HCT-116 colon cancer cells, L-02 and HepG2 hepatoma cells, providing novel evidence for the study of toxic effect and safety evaluation of Si-NPs \[[@CR117], [@CR172]--[@CR174]\]. Endoplasmic reticulum-involved autophagic process (ER autophagy) is a selective form of autophagy in which these organelles can be captured by autophagy process if they are damaged \[[@CR175], [@CR176]\]. Recently, it has been observed that Si-NPs induce endoplasmic reticulum (ER) autophagy in HCT-116 human colon cancer cells without exhibiting a strong cytotoxic effect. The autophagy induced by these nanomaterials was detected by the increase of LC3-II and was associated with the treated time but not by the concentration used. These new findings of Si-NPs-induced ER autophagy could open an effective way for securely designing silica-based nanoparticles and could potentially represent a valid therapeutic tool in autophagy-linked diseases \[[@CR174]\] (Table [2](#Tab2){ref-type="table"}).Table 2NP-Mediated Autophagy in cancer cellsEntryNPCompound carried/combination drugTarget CellsCancer tissue typeAutophagy markersAutophagy mechanismBiological effectReferences1SilverEPS (exopolysaccharide)SKBR3Breast cancerLC-3 ↑Not reportedAutophagy, ROS, cell death\[[@CR112]\]2SilverNonePANC1Pancreatic cancerLC-3 ↑Not reportedAutophagy, ROS, apoptosis, necrosis, cell death\[[@CR113]\]3SilverReduced graphene-oxideHeLaCervical cancerLC-3 ↑, ATGs ↑Not reportedAutophagy, ROS, cell death\[[@CR114]\]4SilverSalymicinA2780Ovarian cancerATGs ↑Not reportedAutophagy, mitochondrial dysfunction, cell death\[[@CR115]\]5SilverRadiotherapyU251GlioblastomaLC-3 ↑, MDC ↑Not reportedAutophagy, ROS, apoptosis, cell death\[[@CR116]\]6SilverNoneHepG2Liver cancerLC-3 ↑Not reportedAutophagy flux, lysosomal activity, apoptosis\[[@CR118]\]7SilverNoneA549Lung cancerLC-3 ↑, ATG-5 ↑; p62 ↑Not reportedAutophagy, apoptosis, mitochondrial damage, cell death\[[@CR119]\]8SilverFungal-derived protein-cappedHuh7, HOS CRL-1543Liver cancer, osteosarcomaLC-3 ↑Not reportedAutophagy, ROS, apoptosis, cell death\[[@CR120]\]9SilverNoneA549Lung cancerLC-3 ↑; p62 ↑Transcription Factor EB ↓Autophagy flux inhibition, lysosome impairment\[[@CR123]\]10GoldpH sensitive\
mPEG-poly(amino ester)s graft copolymersMCF7Breast cancerLC-3 ↑Not reportedAutophagic cell death, lysosome impairment\[[@CR127]\]11GoldSMI\#9SUM1315Breast cancer (TNBC)LC-3 ↑; p62↓Not reportedAutophagy, apoptosis, cell death\[[@CR130]\]12GoldVenom protein toxin (NKCT1)U937, K562LeukemiaLC-3 ↑, Beclin-1 ↑, ATG-3 ↑, ATG-12↑PI3K/Akt/mTOR ↓Autophagy, apoptosis, cell death\[[@CR131]\]13GoldTRIALCalu-1Non-small lung cancer (NSCLC)LC-3 ↑not reportedAutophagy, mitochondrial dysfunction, mitophagy, ROS, apoptosis, cell death\[[@CR132]\]14GoldAnti-EGFR + NIR-PTTMD-MB-231Breast cancer (TNBC)LC-3 ↑, Beclin-1 ↑, ATG-5 ↑, p62 ↓Akt/mTOR ↓Autophagy, cell death\[[@CR134]\]15GoldTmabNCI-N87, MKN7Breast cancer, Gastric cancernot reportedAkt/mTOR ↓Autophagy, cell death\[[@CR136]\]16GoldQuercetin into poly (dl-lactide-*co*-glycolide)MHCC97H, Hep3B, HCCLM3, Bel7402Liver cancernot reportedAkt↓, ERK1/2↓Apoptosis, cell death\[[@CR139]\]17GoldQuercetin into poly (dl-lactide-*co*-glycolide)U87Glioma cancerLC-3 ↑, Beclin-1 ↑, ATG-1 ↑, p62 ↓Akt/mTOR ↓, ERK1/2↓Autophagy, apoptosis, cell death\[[@CR140]\]18GoldQuercetin into poly (dl-lactide-*co*-glycolide)Caski, HeLa, SihaCervical cancerLC-3 ↑mTOR ↓Autophagy, apoptosis, cell death\[[@CR141]\]19GoldPoly (acryloyl-[l]{.smallcaps}, [d]{.smallcaps} and racemic valine)MDA-MB-231Breast cancerLC-3 ↑Not reportedAutophagy, ROS, cell death\[[@CR142]\]20Gold/ironIron core, gold shellOECM1Oral cancerLC-3 ↑Not reportedAutophagy, apoptosis, ROS, mitochondrial damage, cell death\[[@CR144]\]21Gold/ironIron core, gold shellCaco-2, HT-29, SW480Colorectal cancerLC-3 ↑Not reportedAutophagy, apoptosis, ROS, mitochondrial damage, cell death\[[@CR145]\]22Zinc oxideNoneSKOV3Ovarian cancerLC-3 ↑Not reportedAutophagy, apoptosis, ROS, cell death\[[@CR147]\]23Zinc oxideNoneCAL27Oral cancerLC-3 ↑, p62 ↓PINK1/Parkin↑Autophagy, apoptosis, ROS, mitophagy, cell death\[[@CR148]\]24Zinc oxideMeso-tetra (4-carboxyphenyl) porphyrinMCF-7, MDA-MB-468Breast cancerLC-3 ↑, Beclin-1 ↑, ATG-3↑, DRAM-1↑Not reportedAutophagy, apoptosis, cell death\[[@CR149]\]25Iron oxideNoneMCF-7Breast cancerLC-3 ↑, ULK-1 ↑, p62 ↓mTOR ↓Autophagy, ROS, mitochondrial damage, ER stress, apoptosis, cell death\[[@CR151]\]26Iron oxide/goldAnti-EGFR antibodyHCC827Lung cancerLC-3 ↑Not reportedAutophagy, DNA damage, apoptosis, tumor growth suppression\[[@CR152]\]27Iron oxideChitosan chloride (HTCC)/alginateSGC7901, SGC7901/ADRGastric cancerLC-3 ↑, LAMP1↑Not reportedAutophagy, apoptosis, ROS, mitochondrial dysfunction, cell death\[[@CR153]\]28Iron oxideNoneA459Lung cancerLC-3 ↑, ATG-5↑, ATG-12↑mTOR ↓, p70S6K, AMPK ↑Autophagy, ROS, mitochondrial damage, apoptosis, necrosis, cell death\[[@CR154]\]29Iron oxideNoneHeLaCervical cancerLC-3 ↑, p62 ↓mTOR ↓Autophagy\[[@CR155]\]30Iron oxidePEGSKOV3Ovarian cancerLC-3 ↑Not reportedProtective autophagy, ROS, apoptosis, cell death\[[@CR156]\]31Iron oxidePhotothermal treatmentMCF-7Breast cancerLC-3 ↑, p62 ↓Not reportedProtective autophagy\[[@CR157]\]32Cuprous oxideNoneSiHa, Caski, MS751, HeLaCervical cancerLC-3 ↑Akt/mTOR ↓Autophagy, apoptosis, mitochondrial damage, cell death\[[@CR162]\]33Copper oxideNoneMCF7Breast cancerLC-3 ↑, beclin-1 ↑, ATG-5 ↑Not reportedProtective autophagy\[[@CR163]\]34SilicaNoneLBC3GlioblastomaLC-3 ↑, ATG-5↑Not reportedApoptosis, autophagy, mitophagy, ROS\[[@CR169]\]35SilicaNoneHeLaCervical cancerLC-3 ↑; p62 ↑Not reportedAutophagy and lysosomal dysfunction\[[@CR170]\]36SilicaGenistein-PEGylatedHT-29Colorectal cancerautophagosome accumulationNot reportedAutophagy, apoptosis, cell death\[[@CR171]\]37SilicaNoneL-02, HepG2Liver cancerLC-3 ↑, p62↑Not reportedAutophagy, ROS, cell death\[[@CR172]\]38SilicaNoneHepG2Liver cancerLC-3 ↑, p62↑Not reportedAutophagy, ROS, cell death\[[@CR173]\]39SilicaNoneHCT-116HCT-116LC-3 ↑; p62 ↓Not reportedProtective autophagy, ER-autophagy\[[@CR174]\]40SilverNoneB-16 mouse cellMelanomaLC-3 ↑; p62↓PtdIns3K-III ↑Protective autophagy, cell survival\[[@CR182]\]41SilverRadiation treatmentU251GliomaLC-3 ↑ROS dependentROS, mitochondrial damage, protective autophagy\[[@CR185]\]41Ferroferric oxideNoneK562, OCI-AML2; OPM2, RPMI-8226Leukaemia, multiple myelomaLC-3 ↑; p62↓Beclin 1/VPS34/Atg14 complex ↑Protective autophagy, drug resistance\[[@CR186]\]42SilicaNoneA459Lung cancerLC-3 ↑not reportedProtective autophagy, antiapoptotic genes\[[@CR187]\]43SilverNoneHeLaCervical cancerMAPLC3B ↑ SQSTM1/p62 ↑; LAMP1 ↑, CTSB ↑, CTSD↑, ATP6V1H↑mTOR ↓, transcription factor EB nuclear translocationProtective autophagy\[[@CR191]\]44Titanium dioxideNoneHeLaCervical cancerLC-3 ↑transcription factor EB ↑Autophagy\[[@CR206]\]

Other examples of autophagy modulation using nanoparticles {#Sec14}
==========================================================

The use of nanoparticles to modulate autophagy is not just limited to cancer, and a variety of maladies can be treated by this approach, such as muscular or neurodegenerative diseases. Neurodegenerative diseases are a complex set of severe disorders characterized by the progressive loss of neurons leading to severe physical and cognitive inabilities in affected patients. Impairment of autophagy machinery has been reported to be linked with the development of these diseases, and several studies have recently reported that autophagy modulation by nanoparticles may represent a valid therapeutic opportunity.

Cerium oxide nanoparticles (CeO~2~-NPs), due to their antioxidant proprieties, have been exploited for biomedical application \[[@CR177], [@CR178]\]. In addition to protect cells from oxidative stress, these nanomaterials were reported to activate autophagy and promote clearance of autophagic cargo, thus exerting a neuroprotective function. Interestingly, different functionalized CeO~2~-NPs have been shown to enhance autophagic clearance of proteolipid aggregates in fibroblasts derived from a patient with late infantile neuronal ceroid lipofuscinosis (LINCL) that accumulates the autophagic substrate ceroid lipopigment as a result of the inefficient function of the lysosome autophagy system. At the mechanistic level, autophagy induction by CeO~2~-NPs was due to the activation of TFEB that controls the expression of genes involved in lysosomal function and autophagy \[[@CR179]\].

Europium hydroxide nanoparticles \[(EuIII(OH)~3~)-NPs\] has been shown to be able to reduce mutant huntingtin protein aggregation via autophagy induction, which is responsible for many neurodegenerative diseases. The induction of autophagy flux by \[(EuIII(OH)3)-NPs\] has been observed in different cell lines such as Neuro 2a, PC12 and HeLa cells, and it was due to the expression of characteristic autophagy marker LC3-II and degradation of selective autophagy substrate/cargo receptor p62/SQSTM1 \[[@CR180]\] (Table [3](#Tab3){ref-type="table"}).Table 3NP-Mediated Autophagy in other diseases and non-cancer cellsEntryNPCompound carried/combination drugTarget cellsTissue typeAutophagy markersAutophagy mechanismBiological effectReferences1Silverpolyvinylpyrrolidone (PVP)Murine pro-B cells Ba/F3BloodLC-3 ↑; p62 ↓ROS dependent, PI3K--Akt--mTOR ↓Autophagy, DNA damage, apoptosis, cell death\[[@CR117]\]2Cerium oxide*N*-Acetylglucosamine (GlcNAc), polyethylene glycol (PEG), polyvinylpyrrolidone (PVP)FibroblastsLate infantile neuronal ceroid lipofuscinosis type 2 (LINCL)LC-3 ↑, Beclin-1 ↑; p62 ↓, LAMP-1 ↑Transcription factor EB ↑Autophagy, clearance of lipopigment\[[@CR179]\]3Europium hydroxideNoneNeuro 2a, PC12, HeLaNeuronal and cervical cancerLC-3 ↑; p62↓Not reportedAutophagy, clearance of mutant huntingtin\[[@CR180]\]4Iron oxideNoneMonocytesBloodLC-3 ↑; p62 ↓Not reported, probably through VEGFR2--PI3K--Akt--mTORAutophagy, cell survival\[[@CR183]\]5Ferroferric oxideNonePrimary blood cellsBloodLC-3 ↑; p62↓Beclin 1/VPS34/Atg14 complex ↑Autophagy protective\[[@CR186]\]6SilicaNoneMRC-5FibroblastsLC-3 ↑ROS dependentROS, autophagy protective, cell survival\[[@CR188]\]7Iron oxidelactosylated *N*-alkyl polyethylenimineMouse dendritic cellsImmune systemLC-3 ↑Not reportedAutophagy protective\[[@CR189]\]8Bismuth nanoparticlesNoneHEK-293Embryonic kidneyLC-3 ↑, Beclin-1 ↑, ATG12 ↑PI3K/Akt/mTOR ↓, AMPK ↑ROS, autophagy protective\[[@CR190]\]9SilicaNoneHUVECEndothelial cellsLC-3 ↑PI3K/Akt/mTOR ↓Autophagy, mitophagy, ROS, cell death\[[@CR192]--[@CR194]\]10Iron oxide, titanium oxide, silicaAminoPVA \[poly(vinyl alcohol/vinylamine)\]HCECsCerebral endothelial cellsLC-3 ↑; p62 ↓Not reportedROS, DNA damage, autophagy, lysosome activation\[[@CR195]\]10SilicaNoneB4G12, HCECsCorneal endothelial cellsLC-3 ↑Not reportedAutophagy\[[@CR196]\]11SilicaNoneBEAS-2BBronchialLC-3 ↑; p62↑PI3 K/Akt/mTOR↓ROS, autophagy, cytotoxicity\[[@CR197]\]12SilicaNonePC12NeuronalLC-3 ↑, Beclin-1 ↑PI3K/Akt/mTOR↓Autophagy, ROS, cell death\[[@CR198]\]13Iron oxideNoneHUVECEndothelial cellsLC-3 ↑, Beclin-1 ↑, VPS43 ↑Not reportedAutophagy, inflammation\[[@CR199]\]14Titanium dioxideNoneHaCaTKeratinocytesLC-3 ↑, Beclin-1 ↑, ATG5 ↑Not reportedProtective autophagy\[[@CR207]\]15Zinc oxideNoneBV-2MicrogliaLC-3 ↑, Beclin-1 ↑; p62 ↓Not reportedAutophagy, mitochondrial damage, ROS, mitophagy, cell death\[[@CR208]\]16Copper oxidedopamine complexRCSN-3NeuronalLC-3 ↑Not reportedAutophagy, mitophagy, cell death\[[@CR209]\]17Copper oxideNoneHUVECEndothelialLC-3 ↑, Beclin-1 ↑, p62 ↑, ATG-5 ↑Release Cu ionsAutophagy cell death, lysosome dysfunction\[[@CR210]\]17SilverNoneMonocytes THP-1Immune systemLC-3 ↑, p62 ↓Alkalinisation of lysosomesAutophagy blockage, lysosome dysfunction, impairment monocyte differentiation\[[@CR212]\]18Iron oxideNonePeritoneal macrophages RAW264.7Immune systemLC-3 ↑, LAMP-2↑, p62 ↑, ATG-5 ↑Not reportedROS, protective autophagy, cell survival\[[@CR213]\]19Zinc oxideNoneSupT1, Jurkat; Primary human T-cells;Immune systemLC-3 ↑, Beclin-1 ↑Akt/mTOR ↓, release of free Zn^2+^ROS, exacerbate autophagy, DNA fragmentation, cell death\[[@CR214]\]20Zinc oxideNoneMacrophagesImmune systemLC-3 ↑, Beclin-1 ↑PI3K/Akt/mTOR↓ROS, autophagy, apoptosis, cell death\[[@CR215]\]21SilicaNoneMacrophages U937Immune systemNot reportedNot reportedROS, IL-8 production, inflammation, Intracellular Ca^2+^ increase\[[@CR216]\]

As occurs for neurodegenerative diseases, also skeletal muscles are often characterized by impaired autophagy clearance and display accumulation of damaged organelles, or misfolded proteins, inside myofibers. Recently, it has been observed that rapamycin-loaded nanoparticles can rescue a correct autophagy flux in *mdx* mice, a model of Duchenne muscular dystrophy, thus increasing skeletal muscle strength that cannot be achieved with pharmacological doses of conventional oral rapamycin. Therefore, rapamycin-loaded nanoparticles could represent an attractive therapeutic alternative by inducing an autophagy clearance in dystrophic muscles \[[@CR181]\] (Table [4](#Tab4){ref-type="table"}).Table 4In vivo assays performed in the studies reported in the reviewEntryNPCompound carried/combination drugMouse modelDisease modelBiological effectReferences1SilverRadiotherapyOrthotopic mouseBrain cancerEnhancement in mean survival time, increasing cure rate in glioma-bearing rats\[[@CR116]\]2GoldTRAILNude mice bearing Calu-1 cellsnon-small-cell lung cancer (NSCLC)Reduction tumor growth\[[@CR132]\]3GoldTmabSubcutaneous mouse NCI-N87, MKN7Breast cancerGrowth suppression, autophagy induction\[[@CR136]\]4GoldQuercetinOld male BALB/c nu/nu nude mice xenograft modelsGlioblastomaInhibition of tumor growth, low toxicity, improved survival in mice\[[@CR140]\]5GoldQuercetinOld male BALB/c nu/nu nude mice xenograft modelsCervical cancerApoptosis, inhibition cancer growth, and progression\[[@CR141]\]6GoldPoly (acryloyl-[l]{.smallcaps}, [d]{.smallcaps} and racemic valine)BALB/C mice and nude miceBreast cancerAutophagy, reduction tumor growth\[[@CR142]\]7Iron oxide/goldAnti-EGFR antibodyOld female nude miceLung CancerAutophagy, DNA damage, apoptosis, tumor growth suppression\[[@CR152]\]8Iron oxideChitosan chloride (HTCC)/alginateGastric SGC7901/ADR^fluc^ tumor-bearing miceGastric cancerCytotoxicity, autophagy, apoptosis\[[@CR153]\]9Iron oxidePhotothermal treatment, CQMude mice bearing MCF-7 xenograftBreast cancerTumor inhibition, autophagosomes accumulation, apoptosis\[[@CR157]\]10Cuprous oxideNoneCervical carcinoma xenograft in nude miceCervical cancerSuppression tumor growth\[[@CR162]\]11RapamycinNoneC57BL10 mice, C57BL/10ScSn-Dmdmdx/J miceDuchenne muscular dystrophyAutophagy, recovery of skeletal muscle strength\[[@CR181]\]12SilverNoneMale C57BLMelanomaStrong cell growth inhibition in combination with autophagy inhibitor\[[@CR182]\]13SilverNoneAdult male Sprague--Dawley ratsLiver toxicityOxidative stress, markers, hepatotoxicity, protective autophagy\[[@CR184]\]14SilicaNoneNew Zealand white rabbitsOcular toxicityAutophagy, no toxicity reported\[[@CR196]\]

Elevation of autophagy level is a common response of cells upon exposure to metallic nanomaterials, and we have summarized the recent studies reporting that a great variety of these nanostructures may induce autophagy cell death in cancer cells. Paradoxically, in some cases it has been reported that metallic nanoparticles may have opposing roles on the cell fate. Emerging evidence indicates that some metallic nanomaterials induce pro-survival autophagy in both cancer and normal cells \[[@CR120], [@CR156], [@CR182]--[@CR188]\]. For example, ferroferric oxide nanoparticles have been shown to induce pro-survival autophagy in human blood cells by modulating the Beclin1/Bcl-2/VPS34 complex \[[@CR186]\]. Recently, it has also been reported that lactosylated *N*-alkyl polyethylenimine-coated iron oxide nanoparticles induce protective autophagy in mouse dendritic cells \[[@CR189]\]. Bismuth nanoparticles (Bi-NPs) induce protective autophagy in human embryonic kidney cells 293 through the regulation of AMPK/mTOR signal pathway \[[@CR190]\]. It has also been published that Ag-NPs induce protective autophagy in HeLa cells by evoking the nuclear translocation of TFEB and consequently the transcription of autophagy and lysosomal-related genes \[[@CR191]\].

In all these circumstances, inhibition of autophagy becomes a viable approach for enhancing cancer therapeutic efficacy. However, why some metallic nanomaterials induce pro-death autophagy, while others elicit pro-survival autophagy is poorly understood, and the molecular mechanism underlying these two drastically different effects is largely unexplored.

Nanotoxicology {#Sec15}
--------------

Despite the therapeutic advantages of nanomaterials, it is necessary to remind that these products can present some toxicity. Interestingly, the toxicity and the therapeutic effect observed might be derived from the modulation of the autophagy. For instance, Si-NPs have been shown to induce cytotoxicity and autophagy cell death on human umbilical vein, cerebral and corneal endothelial cells through several mechanisms, including ROS generation, dysregulation of PI3K/Akt/mTOR pathway, by affecting angiogenesis and cellular homeostasis, and by leading mitochondrial instability and mitophagy \[[@CR192]--[@CR196]\]. Si-NPs, depending on their size, have also been shown to induce cytotoxicity and autophagy dysfunction in human bronchial epithelial BEAS-2B cells \[[@CR197]\]. This occurred through the upregulation of autophagy markers LC3 and p62, and by modulating PI3K/Akt/mTOR pathway in size- and dose-dependent manner \[[@CR197]\]. This study shows that Si-NPs could lead autophagy dysfunction and impairment of cellular homeostasis in the respiratory system. Moreover, it has been observed that Si-NPs also may induce autophagy and cell death in neuronal PC12 cells \[[@CR198]\]. The autophagy induction, together with ROS increase, and inhibition of ubiquitin--proteasome system (UPS), results in the aggregation of mutant α-synuclein, thus representing a significant risk factor for the development of Parkinson disease \[[@CR198]\]. In addition, high concentrations of magnetic iron oxide nanoparticles (Fe~3~O~4~-NPs) have been reported to lead endothelial dysfunction, inflammation and cardiovascular diseases, through both autophagy induction and the blockade of autophagy flux in HUVECs \[[@CR199]\]. Titanium dioxide nanoparticles (TiO~2~-NPs) are semiconductor nanomaterials that have been explored for drug delivery purposes and are attracting an increasing level of attention \[[@CR200], [@CR201]\]. However, although this nanomaterial has been largely studied for their potent cytotoxic effect in a variety of cancer cells \[[@CR202]--[@CR206]\], it may induce autophagy response in HaCaT human keratinocyte cells \[[@CR207]\]. A recent report showed that ZnO-NPs significantly increased the autophagy, ROS level and mitochondrial impairment in BV-2 microglia cell line, in a time-dependent manner. In addition to changes in autophagy markers, a PINK1/parkin-mediated mitophagy has also been reported. The data reported by the authors suggested that mitophagy could play a protective role in ZnO-NP-induced toxicity in BV-2 cells \[[@CR208]\]. Despite the therapeutic potential of CO-NPs in a variety of cancer cell lines, a specific neurotoxic action of a copper-dopamine complex in neuronal RCSN-3 cells has also been reported. This occurs by inducing mitochondrial autophagy followed by caspase-3-independent apoptotic cell death \[[@CR209]\]. CO-NPs also trigger HUVEC cell death via autophagy and lysosomal dysfunction \[[@CR210]\]. It has been reported that polyvinylpyrrolidone (PVP)-coated Ag-NPs have an anti-leukemia effect against human myeloid leukemia cells \[[@CR182], [@CR185]\]. However, Ag-NPs have also been shown to trigger cytotoxic autophagy in non-cancer murine pro-B cells (Ba/F3) through the modulation of PI3K/mTOR signaling pathway along with generation of ROS and release of silver ions \[[@CR117]\]. Interestingly, some studies report that metallic nanomaterials possess intrinsic toxicity versus immune system components by modulating autophagy. Among the plethora of cells that constitute the immune system, macrophages mediate innate immune responses and contribute to adaptive immunity via antigen processing \[[@CR211]\]. It has been reported that Ag-NPs impair monocyte--macrophage differentiation through autophagy blockade, which is mediated by lysosomal dysfunction. Indeed, lysosomal impairment was observed in Ag-NP-treated THP-1 cells, which is responsible for the blockade of autophagic flux \[[@CR212]\]. This study suggests a crosstalk among monocyte differentiation, autophagy, and lysosomal dysfunction simultaneously induced by Ag-NPs. In addition, Fe~3~O~4~-NPs have been reported to induce pro-survival autophagy in RAW264.7 cells derived from mouse peritoneal macrophages. The induction of autophagy markers and ROS levels after treatment with Fe~3~O~4~-NPs were accompanied by the ERK pathway that was activated for cell survival \[[@CR213]\]. Interestingly, it has been reported that acute exposure to ZnO-NPs induces autophagic immune cell death. This occurs by the release of free Zn(2+) that can be taken up by immune cells triggering the production of excessive intracellular ROS that leads to exacerbated autophagy \[[@CR214], [@CR215]\]. Many other studies reported that Si-NPs possess strong toxicity against immune components through the enhancement of proinflammatory responses, oxidative stress and autophagy modulation \[[@CR216], [@CR217]\]. These and other studies (reviewed in Peynshaert, 2014) indicate that autophagy modulation mediated by inorganic NPs can potentially represent a risk for immune system, cardiovascular and neurological health. However, the involvement and nature of autophagy deregulation in the pathogenesis of the above-described diseases need further investigation before making conclusions regarding the real cardiovascular and neurological dangers of these nanomaterials and to eventually efficiently target autophagy as a therapeutic strategy.

Conclusion and future perspective {#Sec16}
=================================

Human tumors are complex diseases resulting from the interplay between genetic and environmental factors. Besides the many cellular and genetic alterations, cancer cells share common features responsible for their phenotypic manifestations, including uncontrolled proliferation and growth, dysregulation of apoptosis and insensitivity, and severe metabolic alterations \[[@CR2]\]. Autophagy is a tightly regulated cellular degradative process by which damaged macromolecules and organelles are targeted by autophagic vesicles to lysosomes and then eliminated \[[@CR218]\]. Autophagy is frequently dysregulated in tumors, however, its role in regulating cancer cell death or survival remains highly debated and dependent on metabolic context and on the microenvironmental conditions of the cells \[[@CR219]\]. Some studies suggest that basal autophagy may have a protective role in cancer by providing the nutrients necessary for their uncontrolled growth as well as favoring cancer cell survival in many hypoxic tumor microenvironments \[[@CR48]\]. However, it is also well assumed that overstimulating autophagy machinery can also lead to cell death, also called cell death-type II, likely due to excessive degradation of cellular constituents and organelles required for homeostasis of the cells \[[@CR46]\]. There is mounting evidence that targeting autophagy may be employed as a therapeutic strategy itself or may enhance the efficacy of anticancer therapies \[[@CR71], [@CR220]\]. The field of nanotechnology is greatly expanding and can provide the necessary tools to overcome the limits frequently observed with traditional treatments.

This review presents an overview of the most recent reports on NP-mediated autophagy alterations and their impact on nanomedicine. Many studies have shown that nanomaterials and particularly metallic nanoparticles can be used to treat cancer by modulating autophagy. These nanostructures may also promote a plethora of events such as mitochondrial damage, lysosome impairment, ER stress and alterations of signaling pathways, which results in the activation of mitophagy, oxidative stress, and autophagic cell death. Importantly, these materials have shown intrinsic selectivity in inducing autophagy in cancer cells compared to noncancerous cells. However, metal-based nanomaterials may have opposing roles on cell fate being able to induce pro-survival autophagy in cancer and normal cells \[[@CR162], [@CR184]--[@CR189]\]. Thus, inhibition of autophagy may be a viable approach for enhancing cancer therapeutic efficacy.

Autophagy induced by nanomaterials can also be used to treat other diseases such as muscular and neurodegenerative disorders. It is due to their ability to restore a proper autophagic flux, thus removing the protein aggregates and damaged organelles, responsible for the pathogenesis of these diseases \[[@CR64], [@CR68]\].

Hence, the capability of many nanostructures to overstimulate autophagy may acquire exceptional medical and toxicological importance. However, more research is needed to define the mechanisms underlying the NP-induced autophagy modulation.

In conclusion, the findings summarized in this review suggest that autophagy modulation with nanoparticle-based strategies would acquire clinical relevance in the near future, as complementary therapies for the treatment of cancers and other diseases.
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